Elsevier

Annals of Oncology

Volume 22, Supplement 6, September 2011, Pages vi78-vi84
Annals of Oncology

supportive care
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines

https://doi.org/10.1093/annonc/mdr391Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Approved by the ESMO Guidelines Working Group: January 2008, last update July 2011. This publication supersedes the previously published version—Ann Oncol 2010; 21 (Suppl 5): v261-v265.

Conflict of interest: Professor Peterson has reported that he is Principal Investigator on an NIH R13 Conference Grant that provided partial support for the symposium ‘Oral Complications of Emerging Cancer Therapies’, 14–15 April 2009, Bethesda, MD, USA. Production of a JNCI Monograph for the conference publications is being supported via an unrestricted educational grant from Swedish Orphan Biovitrum, which currently owns palifermin. He has also reported that he is a member of the Scientific Advisory Board and a paid consultant for The GI Co., Inc. This company has been responsible for development of recombinant intestinal trefoil factor, for which the phase II study is cited in the literature section (reference 19, J Clin Oncol 2009). Professor Peterson is also a Consultant for Alder BioPharmaceuticals, Inc.; Merck & Co., Inc.; and Otsuka Pharmaceutical Development & Commercialization, Inc. Professor Bensadoun has reported no conflicts of interest in 2011. In 2010, Professor Bensadoun was a consultant for BioAlliance Pharma, Novartis and Amgen. Dr Roila has reported no conflicts of interest.